Atea defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial ...

As part of Xenon's ongoing collaboration with Neurocrine Biosciences, a Phase 1 study is underway of NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and ...

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and ...

Topline data were announced from two phase 3 studies evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

OmniAb's reliance on licensing transgenic animals for drug discovery faces risks with FDA shifts and cash burn issues. Learn ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based ...

Researchers have discovered a promising new drug combination that significantly lowers “bad” LDL cholesterol for people whose ...

The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly ...